Please assess the completion status of the following clinical trial:

Trial Title: Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 years or older at the time of consent~2. Able to give informed consent~3. Subjects with high grade BCG-refractory or relapsed NMIBC including~   * High grade non-invasive papillary carcinomas (Ta) and subjects with high grade tumors that invade sub-epithelial connective tissue (T1) or~  * Carcinoma in situ (CIS) only or~  * CIS and Ta or T1 tumors Refractory is defined as failure to achieve a disease-free state at six months after adequate induction of BCG therapy with either maintenance or re-induction at 3 months. Adequate induction is defined as a minimum of 5 out of 6 induction doses and adequate maintenance is defined as a minimum of 2 out of 3 doses of treatment.~   Relapse is defined as recurrence within 1 year after a complete response to BCG treatment~4. Complete resection of visible papillary lesions or CIS by TURBT or endoscopic resection between 14 and 60 days prior to beginning study treatment~5. Available for the whole duration of the study~6. Life expectancy \>2 years, in the opinion of the investigator~7. ECOG status 2 or less~8. Absence of upper tract urothelial carcinoma~9. Female subjects of childbearing potential must use maximally effective birth control during the period of therapy, must be willing to use contraception for 1 month following the last study drug infusion and must have a negative urine or serum pregnancy test upon entry into this study. Otherwise, female subjects must be postmenopausal (no menstrual period for a minimum of 12 months) or surgically sterile.~10. Male subjects must be surgically sterile or willing to use a double barrier contraception method upon enrollment, during the course of the study, and for 1 month following the last study drug infusion.~11. Adequate laboratory values.~    * Hemoglobin ≥10 g/dL.~   * WBC ≥4000/μL.~   * ANC ≥2000/μL.~   * Platelet count ≥100,000/μL.~   * INR within institutional normal limits.~   * aPTT within institutional normal limits.~   * AST ≤1.5 x ULN.~   * ALT ≤1.5 x ULN.~   * Total bilirubin within institutional normal limits.~   * Creatinine ≤1.5 x ULN.~Exclusion Criteria:~1. Current or previous evidence of muscle invasive or metastatic disease~2. Current systemic therapy for bladder cancer~3. Current or prior pelvic external beam radiotherapy~4. Prior treatment with adenovirus-based drugs~5. Suspected hypersensitivity to interferon alpha~6. Existing urinary tract infection or bacterial cystitis~7. Clinically significant and unexplained elevated liver or renal function tests~8. Women who are pregnant or lactating~9. Severe cardiovascular disease~10. History of malignancy of other organ system within past 5 years (except treated basal cell carcinoma or squamous cell carcinoma of the skin)~11. Subjects who cannot hold instillation for 1 hour~12. Subjects who cannot tolerate intravesical dosing or intravesical surgical manipulation~13. Intravesical therapy within 6 weeks of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rAd-IFN Dose 1x10^11vps/ml (Type: EXPERIMENTAL): Subjects will be randomly assigned to one of two INSTILADRIN arms.
- rAd-IFN dose 3x10^11 vps/ml (Type: EXPERIMENTAL): Subjects will be randomly assigned to one of two INSTILADRIN arms.

Based on this trial design, predict the completion outcome and termination type (if applicable).